المؤلفون: Juan R. Gimeno, Iacopo Olivotto, Ana Isabel Rodríguez, Carolyn Y. Ho, Adrián Fernández, Alejandro Quiroga, Mari Angeles Espinosa, Cristina Gómez‐González, María Robledo, Lucas Tojal‐Sierra, Sharlene M. Day, Anjali Owens, Roberto Barriales‐Villa, Jose María Larrañaga, Jose Rodríguez‐Palomares, Maribel González‐del‐Hoyo, Jesús Piqueras‐Flores, Nosheen Reza, Olga Chumakova, Euan A. Ashley, Victoria Parikh, Matthew Wheeler, Daniel Jacoby, Alexandre C. Pereira, Sara Saberi, Adam S. Helms, Eduardo Villacorta, María Gallego‐Delgado, Daniel deCastro, Fernando Domínguez, Tomás Ripoll‐Vera, Esther Zorio‐Grima, José Carlos Sánchez‐Martínez, Ana García‐Álvarez, Elena Arbelo, María Victoria Mogollón, María Eugenia Fuentes‐Cañamero, Elias Grande, Carlos Peña, Lorenzo Monserrat, Neal K. Lakdawala, Dilema International Cardiomyopathy and Heart Failure Registry and international SHaRe (Sarcomeric Human Cardiomyopathy Registry) Investigators group

المصدر: ESC Heart Failure, Vol 9, Iss 4, Pp 2189-2198 (2022)

مصطلحات موضوعية: Hypertrophic cardiomyopathy, COVID‐19, SARS‐CoV‐2 infection, Heart failure, Registry, Prognosis, Diseases of the circulatory (Cardiovascular) system, RC666-701

الوصف: Abstract Aims To describe the natural history of SARS‐CoV‐2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. Methods and results Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS‐Cov‐2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS‐CoV‐2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty‐nine (22.9%) HCM patients were hospitalized for non‐ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS‐CoV‐2‐related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one‐unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community‐based SARS‐CoV‐2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600). Conclusions Over one‐fourth of HCM patients infected with SARS‐Cov‐2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2055-5822

URL الوصول: https://doaj.org/article/91483f6a810740f68b374d86c8670633

المؤلفون: Raquel López‐Vilella, Silvia Lozano‐Edo, Patricia Arenas Martín, Pablo Jover‐Pastor, Meryem Ezzitouny, José Sorolla Romero, María Calvo Asensio, Julia Martínez‐Solé, Borja Guerrero Cervera, José Carlos Sánchez Martínez, Víctor Donoso Trenado, Ignacio Sánchez‐Lázaro, Luis Martinez Dolz, Luis Almenar Bonet

المصدر: ESC Heart Failure, Vol 9, Iss 1, Pp 133-145 (2022)

مصطلحات موضوعية: Ferric carboxymaltose, Iron deficiency, Heart failure, Preserved ejection fraction, Reduced ejection fraction, Ferritin, Diseases of the circulatory (Cardiovascular) system, RC666-701

الوصف: Abstract Aims Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). Methods and results We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin 0.05). Conclusions Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2055-5822

URL الوصول: https://doaj.org/article/663f4ac059874248baec8e9edc3774f6